Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Scandion Oncology A/S (8VY.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.2420+0.0090 (+3.86%)
At close: 09:15AM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.2330
Open0.2420
Bid0.2390 x N/A
Ask0.2640 x N/A
Day's Range0.2420 - 0.2420
52 Week Range0.1760 - 1.6980
Volume500
Avg. Volume7
Market Cap10.646M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-0.2330
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 8VY.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02

      COPENHAGEN, Denmark, March 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now finalized recruitment for Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma patients. The Company already conducts the successful EVX-01 program with clinical testing in Australia, Europe and the US, where app. 100 patients suffering from malignant melanoma (metastasized skin cancer) will be

    Advertisement
    Advertisement